查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1268945

2023-2030 年全球骨质疏鬆症检测市场

Global Osteoporosis Testing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球骨质疏鬆症检测市场预计将实现利润丰厚的增长，到 2022 年将达到 3.835 亿美元，到 2030 年将达到 5.668 亿美元。 预计全球骨质疏鬆症检测市场在预测期内（2023-2030 年）的复合年增长率为 5.1%。 由于 X 射线的日益普及和 X 射线最终用途的日益多□□样化，预计在预测期内，骨质疏鬆症检测市场对诊断影像服务的需求将会增加。

例如，2020 年，RadNet 和 Dignity Health 在亚利桑那州成立了一家合资企业。 该合资企业支持 Dignity Health 和 RadNet 目前向患者和目标医疗保健社区提供服务的承诺。 例如，Philips N.V. 将在 2021 年推出一款新的 CT，即 Spectral CT 7500，主要用于精准诊断。

影响全球骨质疏鬆症检测市场的因素是技术进步和骨质疏鬆症患病率的增加。 骨质疏鬆症是一种随着时间的推移而恶化的疾病。 结果，骨头可能变得多孔并容易折断。 双能 X 射线吸收测定法，也称为 DXA 或 DEXA 扫描，是目前诊断骨质疏鬆症的金标准。

然而，产品的高成本预计会阻碍市场增长。 例如，DXA 设备的成本估计超过 100,000 美元，占与其使用相关的大部分成本。 然而，DXA 比现场检查更适合实验室调查。

市场动态

技术的进步带动了市场的增长，是推动市场增长的主要因素之一。

已使用多种技术来评估骨骼健康，其中最常见的是双能 X 射线吸收测定法 (DXA)，它可以测量脊柱、臀部或全身。 成像技术的最新进展使骨骼健康评估更快、更准确。

例如，位于马萨诸塞州贝德福德的 Hologic 的 Discovery QDR 系列骨密度计具有高清即时椎骨评估 (IVA) 功能，可扫描腰椎和胸椎 10 秒以检测椎骨畸形。我来了。 这使得更多患者被归类为患有骨质疏鬆症，即使 BMD 结果处于临界状态。

医生可以使用它来快速拍摄图像并确定是否存在椎骨压缩性骨折。 这些进步旨在提高 DXA 基础骨密度系统的效用，以全面评估患者的健康状况，预计将在预测期内推动骨质疏鬆症检测市场的增长。

与骨质疏鬆症检测相关的限制阻碍了市场增长。

DXA 测试无法预测谁会骨折。 儘管 DXA 可有效测量骨密度，但它在脊柱畸形或接受过脊柱手术的人群中的使用有限。

随着更好的成像扫描仪的发展，准确测量这些骨骼参数对于推进骨折风险评估和告知临床医生最佳治疗策略至关重要。

此外，虽然所有基于 X 射线的方法都可以测量 BMD，但该参数只能解释 60%–80% 的骨强度变化，而密度测定技术无法评估骨质流失。我们展示了力学方面 (的微观结构参数、骨骼几何形状、弹性特性） 因此，这些因素可能会阻碍预测期内的市场增长。

COVID-19 影响分析

在 COVID-19 大流行期间，筛查、诊断和治疗骨质疏鬆症患者已被证明具有挑战性。 患者进入代谢性骨科诊所的机会被打乱，由于治疗延误导致未来出现问题，尤其是狄诺塞麦患者。

在大流行期间，新发术后脆性和髋部骨折患者的骨质疏鬆症护理质量急剧下降。 因此，全球骨质疏鬆症检测市场受到 COVID-19 的负面影响。

一些医学协会提出了在大流行期间促进患者和工作人员安全的建议，包括双能 X 射线吸收测定法 (DXA) 骨密度测定法。还包括国际临床骨密度测定联合会 (ISCD)，该组织已受到影响受到危机的影响，并意识到它处于中断状态。

俄乌衝突分析

俄罗斯和乌克兰之间的衝突中断了一些用于骨质疏鬆症检测的设备的供应链，增加了消费者的成本并使其难以获得他们需要的检测。 这些因素对骨质疏鬆症检测市场产生了重大影响。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 片段类型
  • 最终用户的片段
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 技术进步
    • 约束因素
      • 与骨质疏鬆症检测相关的限制
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第 7 章按类型

  • X光扫描
    • 德克萨
  • FRAX 工具
  • 定量超声扫描

最终用户第 8 章

  • 医院
  • 影像诊断中心
  • 骨科诊所
  • 门诊手术中心

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 竞争场景
  • 市场分析/份额分析
  • 併购分析

第11章公司简介

  • 通用电气医疗
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • DMS Imaging
  • Swissray
  • BeamMed
  • Hologic
  • OSTEOSYS
  • Scanflex Healthcare
  • CompuMed
  • FUJIFILM
  • Trivitron Healthcare

第12章 附录

简介目录
Product Code: MD5018

Market Overview

The global osteoporosis testing market reached US$ 383.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 566.8 million by 2030. The global osteoporosis testing market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The growing adoption of X-rays and the rise in the various end-use applications of X-rays are expected to drive demand for diagnostic imaging services in the osteoporosis testing market during the forecast period.

For instance, in 2020, RadNet and Dignity Health launched a collaborative venture in Arizona. This venture aided in Dignity Health and RadNet's current commitment to provide patients and targeted medical communities. For instance, Philips N.V. launched a newer version of CT in 2021 called Spectral CT 7500, which is primarily used for precision diagnosis.

The factors influencing the global osteoporosis testing market are technological advancements and the increasing prevalence of osteoporosis. Osteoporosis is a disease that can worsen over time. This can cause the bone to become more porous and prone to breaking. Dual Energy X-ray Absorptiometry, also known as a DXA or DEXA scan, is the current gold-standard method for diagnosing osteoporosis.

However, the high cost of the product is expected to hamper the market growth. For instance, the cost of the DXA instrument, which is likely to exceed US$ 100,000, accounts for the majority of the costs associated with its use. However, DXA is better suited to lab-based research rather than field testing.

Market Dynamics

The technological advancements lead to the market's growth and is one of the main factors driving the market growth.

A variety of technologies have been used to assess skeletal health, the most common of which is dual-energy X-ray absorptiometry (DXA), which measures the spine, hip, or entire body. The skeletal health assessment has become faster and more accurate due to recent advances in imaging technology.

For instance, the Hologic, Bedford, MA-based Discovery QDR Series bone densitometer includes High-Definition Instant Vertebral Assessment (IVA), which takes a 10-second scan of the lumbar, thoracic spine to detect vertebral deformities. This allows classifying more patients as osteoporotic, even if their BMD results are borderline.

The physician can use this to take quick images and determine whether there is a vertebral compression fracture. These advancements aim to improve the DXA basic bone density system's utility in assessing overall patient health and are expected to drive osteoporosis testing market growth over the forecast period.

Limitations associated with osteoporosis testing are factors hindering the market growth.

A DXA test cannot predict who will fracture. DXA is of limited use in people with a spinal deformity or those who have had previous spinal surgery, despite its effectiveness in measuring bone density.

Accurate measurement of these skeletal parameters through the development of better imaging scanners is critical to advancing fracture risk assessment and informing clinicians on the best treatment strategy.

Moreover, all the X-ray-based methods provide a measure of BMD but this parameter can explain only 60%-80% of the variability in bone strength, and it has demonstrated other mechanical aspects of the bone (microarchitectural parameters, bone geometry, and elastic properties), which cannot be assessed by densitometric techniques. Thus, these factors will hamper the market growth over the forecast period.

COVID-19 Impact Analysis

During the COVID-19 pandemic, screening, diagnosis, and treatment of patients with osteoporosis proved difficult. Patients' access to metabolic bone clinics has been disrupted, causing future problems due to treatment delays, particularly in denosumab patients.

During the pandemic, the quality of osteoporosis care for patients who suffered a new fragility fracture or hip fracture following surgery deteriorated drastically. Hence, the global osteoporosis testing market was negatively impacted by COVID-19.

Several medical societies provided recommendations to promote patient and staff safety during the pandemic, including the International Society for Clinical Densitometry (ISCD), which recognized that bone densitometry testing with dual-energy x-ray absorptiometry (DXA) has been affected and idled by the crisis.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has caused a disruption of the supply chain for some of the equipment used in osteoporosis testing, increasing costs for consumers and making it more difficult for them to access the necessary testing. These factors have had a significant impact on the osteoporosis testing market.

Segment Analysis

The global osteoporosis testing market is segmented based on type, end user and region.

The X-ray scan segment will be dominated by market players during the forecast period.

The X-ray scan segment accounted for the highest market share accounting for approximately 59.7% of the osteoporosis testing market in 2022. X-ray is very helpful and crucial in the diagnosis of osteoporosis. The key X-ray finding indicative of osteoporosis is the loss of bone mass. The main loss is found in the bony trabecula rather than the cortex. The results of a bone density scan are generally utilized alongside a fracture risk assessment to evaluate the chances of breaking a bone or osteoporosis.

Anyone can get affected by osteoporosis at any age, although post-menopausal older women are at high risk. This is due to the decline of estrogen levels after menopause, which results in low bone density. The more dense the bones are, the less likely and stronger they are to get fractured or broken. Osteoporosis may not show any symptoms until a fracture of the bone.

Geographical Analysis

North America holds a dominant position in the market.

North America held 38.5% osteoporosis testing market share in 2022. The most prevalent bone disease, osteoporosis, which affects roughly 10 million people in the U.S. alone, causes bones to become weak and prone to fractures. According to AMGA Foundation, nearly 54 million Americans have osteoporosis or low bone density, and approximately one in two women and one in four men aged 50 and older will break a bone due to osteoporosis. Fractures often have a devastating effect on patients and lead to billions in direct care costs each year.

Many people with osteoporosis do not know they have the disease until after a broken bone. Unfortunately, recent evidence shows that even after a fracture, less than 15 percent of commercially insured US patients receive treatment for osteoporosis.

Competitive Landscape

The major global players include: GE Healthcare, DMS Imaging, Swissray, BeamMed, Hologic, OSTEOSYS, Scanflex Healthcare, CompuMed, FUJIFILM, and Trivitron Healthcare among others.

Why Purchase the Report?

  • To visualize the global osteoporosis testing market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global osteoporosis testing market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global osteoporosis testing market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by End User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Limitations associated with osteoporosis testing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. X-Rays Scan*
    • 7.2.1. DEXA
    • 7.2.2. Introduction
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. FRAX Tool
  • 7.4. Quantitative Ultrasound Scans

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospital*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Imaging Centers
  • 8.4. Orthopedic Clinics
  • 8.5. Ambulatory Surgery Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. GE Healthcare*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. DMS Imaging
  • 11.3. Swissray
  • 11.4. BeamMed
  • 11.5. Hologic
  • 11.6. OSTEOSYS
  • 11.7. Scanflex Healthcare
  • 11.8. CompuMed
  • 11.9. FUJIFILM
  • 11.10. Trivitron Healthcare

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us